4.5 Review

Dementia time to death: a systematic literature review on survival time and years of life lost in people with dementia

期刊

INTERNATIONAL PSYCHOGERIATRICS
卷 24, 期 7, 页码 1034-1045

出版社

CAMBRIDGE UNIV PRESS
DOI: 10.1017/S1041610211002924

关键词

dementia; survival; mortality; death; life expectancy; Alzheimer's disease

资金

  1. Eisai Pharmaceuticals
  2. Eli Lilly and Company
  3. GlaxoSmithKline
  4. H Lundbeck A/S
  5. Janssen-Cilag Pty Limited
  6. Medivation Inc.
  7. Novartis Pharmaceuticals
  8. Pfizer Inc.
  9. Prana Biotechnology Limited
  10. sanofi-aventis
  11. Voyager Pharmaceutical Corporation
  12. Wyeth Limited

向作者/读者索取更多资源

Background: Life expectancy with dementia directly influences rates of prevalence and service needs and is a common question posed by families and patients. As well as years of survival, it is useful to consider years of life lost after a diagnosis of dementia. Methods: We systematically reviewed the literature on mortality and survival with dementia which were compared to estimated life expectancies in the general population. Both were then compared by age (under 65 years vs. 65+ years), gender, dementia type, severity, and two epochs (prior to and after introduction of cholinesterase inhibitors in 1997). Results: Survival after a diagnosis of dementia varies considerably and depends on numerous factors and their complex interaction. Relative loss of life expectancy decreases with age at diagnosis across varying gender, dementia subtypes (except for frontotemporal dementia and dementia with Lewy bodies), and severity stages. Numerous study deficiencies precluded a meta-analysis of survival in dementia. Conclusion: Estimates of years of life lost through dementia may be helpful for patients and their families. Recommendations for future research methods are proposed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据